Do you want to read an article? Please log in or register.
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
Breast Cancer
Related content
Breast Cancer
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Lancet Oncol
Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Viale G, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Gelber R, Loibl S
doi: 10.1016/S1470-2045(25)00546-7
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
Breast Cancer
Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials
Lancet Oncol
Pfob A, Pham TH, de Boniface J, Gentilini OD, Loibl S, Schneeweiss A, Postma M, van Asselt ADI, Reimer T, Heil J
doi: 10.1016/S1470-2045(26)00064-1
RECOMMENDED
Breast Cancer
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
O'Brien KM, House MG, Goldberg M, Jones ME, Weinberg CR, de Gonzalez AB, Bertrand KA, Blot WJ, DeHart JC, Couch FJ, Garcia-Closas M, Giles GG, Kirsh VA, Kitahara CM, Koh WP, Park HL, Milne RL, Palmer JR, Patel AV, Rohan TE, Schoemaker MJ, Swerdlow AJ, Teras LR, Vachon C, Visvanathan K, Yuan JM, Zheng W, Nichols HB, Sandler DP
doi: 10.1016/S1470-2045(25)00211-6
Breast Cancer
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Lancet Oncol
Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M
doi: 10.1016/S1470-2045(26)00053-7
CHICAGO 2026
Breast Cancer
NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer
Breast Cancer
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis
Cancer Treat Rev
Yucel KB, Ilhan Y, Almuradova E, Bardakci M, Dinckal C, Ergun Y
doi: 10.1016/j.ctrv.2025.103074
Lung, Respiratory and Thoracic Cancer
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open
Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S
doi: 10.1016/j.esmoop.2025.105870
ESMO 2025
Breast Cancer